Intellectual Property

LMG Life Sciences Americas Awards (2025)

LMG Life Sciences Americas Awards (2025)

Managing IP Americas Awards (2025)

LSPN Awards USA (2026)

LSPN Awards USA (2026)

LMG Life Sciences Americas Awards (2026)

LSPN Awards USA (2025)

Managing IP (2025)

IAM Patent 1000 (2025)

IAM Patent 1000 (2025)

Google: Won complete victories in inter partes reviews (IPRs) and appeals challenging nine Virentem multimedia patents, leading to dismissal of the district court case after the Supreme Court denied review.

AbbVie/Allergan: Secured a precedent-setting Federal Circuit ruling protecting first-filed, first-issued patents from obviousness-type double patenting challenges and reversing a written-description ruling against Viberzi® patents. The victory earned “Impact Case of the Year” at both the 2025 Managing IP Americas Awards and the 2025 LMG Life Sciences Americas Awards.

Samsung: Won a precedent-setting Federal Circuit ruling confirming that published patent applications may serve as prior art in IPRs as of their filing date.

BioMarin Pharmaceutical: Secured a global settlement of an ITC patent dispute over achondroplasia therapies, providing a 20% royalty on U.S. net sales of Ascendis Pharma’s Yuviwel® for the remaining life of the asserted patent—just days before the ITC’s initial determination deadline.

Chevron: Delivered a complete victory in Pilot Energy Solutions’ natural gas recovery patent and misrepresentation suit, winning dismissal of the misrepresentation claims and filing an IPR that led Pilot to dismiss the case with prejudice.

Eisai and Merck: Won a complete Hatch-Waxman trial victory protecting blockbuster cancer therapy Lenvima® in one of the first cases testing patent claims covering highly pure forms of an active ingredient. Defeated all remaining invalidity challenges.

bluebird bio (now Genetix Biotherapeutics) and Third Rock Ventures: Won summary judgment of noninfringement in a $2 billion gene therapy patent dispute, following dismissal of related trade secret, RICO, and antitrust litigation.

Google: Invalidated all challenged claims across five asserted VoIP patents through a coordinated district court, PTAB, and appellate strategy, securing Federal Circuit affirmance and dismissal of the district court case.

Tanabe Pharma and Mitsubishi Chemical Group: Secured an international arbitration award directing Novartis to pay $2 billion in Gilenya® royalties plus more than $22 million in fees and costs. Separately, defeated generic challenges to Tanabe Pharma’s Gilenya® patent in Hatch-Waxman litigation, establishing new law on obviousness-type double patenting.

AbCellera and UBC: Defeated three IPR challenges and a Federal Circuit appeal involving foundational antibody-discovery patents, culminating in a global settlement from a Northern District of California infringement action providing AbCellera $36 million plus continuing royalties on its competitor’s worldwide sales.

Samsung: Invalidated all challenged claims of Broadphone’s mobile device location patents in four IPRs, prompting dismissal of the district court claims against Samsung with prejudice.

Inpria and JSR Corporation: Defeated temporary restraining order and preliminary injunction requests threatening Inpria’s core semiconductor technology and JSR’s planned $6.4 billion acquisition by Japan Investment Corporation.

BioNTech: Successfully challenged two Moderna patents in IPR proceedings and secured a stay of the related federal district court litigation. This came on the heels of our obtaining the dismissal of patent infringement claims brought by Promosome and successfully settling claims brought by CureVac.

Daiichi Sankyo: Won a complete arbitration victory defeating Seagen’s claims to tens of billions of dollars and rights to a pioneering cancer drug portfolio. Secured more than $45 million in fees and costs—one of the largest known such awards in international commercial arbitration—and defeated Seagen’s bid to overturn the award.

Chevron: Defeated SNF’s IPR challenge to a patent covering offshore polymer flooding technology, preserving every claim protecting Chevron’s enhanced oil recovery innovation.

Tanabe Pharma: Defeated every patent challenge to blockbuster diabetes medication Invokana® in the District of New Jersey’s first-ever virtual Hatch-Waxman trial.

L’Oréal USA: Eliminated an infringement theory covering all 130 accused L’Oréal products in an adenosine patent dispute brought by the University of Massachusetts and Carmel Laboratories.

AbbVie and Genentech: Secured complete resolution of Hatch-Waxman litigation protecting Venclexta®, a treatment for leukemia and lymphoma, following a decisive victory against a generic challenger’s PTAB challenges.